Overview

Envarsus XR Compared to Immediate Release Tacrolimus

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare once-daily tacrolimus extended-release (Envarsus XR®) to twice-daily immediate release tacrolimus to find out if people taking tacrolimus extended release (Envarsus XR®) report fewer side effects, increased medication compliance and higher scores on quality of life assessments compared to people taking twice daily tacrolimus immediate release.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Veloxis Pharmaceuticals
Treatments:
Tacrolimus